The objective of this review is to evaluate the efficacy and safety of plasmapheresis (alone or in combination with other immunomodulating treatment) in patients with relapsing-remitting or secondary progressive or primary progressive MS. We want to evaluate the principal hypothesis that plasmapheresis, performed during the relapses, can: 1. Improve disability after a relapse; 2. Reduce the number of relapses during the follow-up; 3. Prevent disability progression on long observation. Moreover, we want to evaluate whether plasmapheresis performed during the progressive course can delay disability progression during the follow-up of patients with primary of secondary progressive MS. The secondary aims are to evaluate if the effect of the treatment is different according to: 1. The type of course of MS; 2. The duration of the disease prior the beginning of the treatment with plasma exchange.
Plasma exchange for multiple sclerosis
CASETTA, Ilaria;
2010
Abstract
The objective of this review is to evaluate the efficacy and safety of plasmapheresis (alone or in combination with other immunomodulating treatment) in patients with relapsing-remitting or secondary progressive or primary progressive MS. We want to evaluate the principal hypothesis that plasmapheresis, performed during the relapses, can: 1. Improve disability after a relapse; 2. Reduce the number of relapses during the follow-up; 3. Prevent disability progression on long observation. Moreover, we want to evaluate whether plasmapheresis performed during the progressive course can delay disability progression during the follow-up of patients with primary of secondary progressive MS. The secondary aims are to evaluate if the effect of the treatment is different according to: 1. The type of course of MS; 2. The duration of the disease prior the beginning of the treatment with plasma exchange.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
